High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18

International Journal of Cancer

Volumn 120, Issue 8, 2007, Pages 1763-1768

  Sichero, Laura ^a,b   Ferreira, Silvaneide ^a   Trottier, Helen ^c   Duarte Franco, Eliane ^c   Ferenczy, Alex ^c   Franco, Eduardo Luis ^c   Villa, Luisa Lina ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Cervical neoplasia; Cohort study; Human papillomavirus; Molecular variants; Oncogenic potential

Indexed keywords

ADULT; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS STRAIN;

ADOLESCENT; ADULT; BRAZIL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; DNA, VIRAL; FEMALE; GENES, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; MIDDLE AGED; MUTATION; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS; VARIATION (GENETICS); VIRAL LOAD;

EID: 33947121724     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22481     Document Type: Article

References (51)

1. Muñoz N, Bosch FX, de Sanjose S, Herrera R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003;348:518-27.
2. Münger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89:213-28.
3. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003;95:1336-43.
4. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, Franco EL. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000;81:2959-68.
5. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, Peyton CL, Bauer HM, Wheeler CM. Identification and assessment of known and novel human papillomaviruses by polimerase chain reaction amplification, restriction fragment polymorphisms, nucleotide sequence, and phylogeny algorithms. J Infect Dis 1994;170:1077-85.
6. Chen Z, Terai M, Fu L, Herrera R, DeSalle R, Burk RD. Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J Virol 2005;79:7014-23.
7. Ho L, Tay SK, Chan SY, Bernard HU. Sequence variants of human papillomavirus type 16 from couples suggest sexual transmission with low infectivity and polyclonality in genital neoplasia. J Infect Dis 1993;168:803-9.
8. Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromana-Nazos P, Labropoulou V, Pfister H, Tay SK, ter Meuler J, Villa LL, Bernard HU. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 1993;67:6424-31.
9. Yamada T, Manos MM, Peto J, Greer CE, Muñoz N, Bosch X, Wheeler CM. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997;71:2463-72.
10. Berumen J, Ordonez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, Yunes E, Garcia-Carranca A, Gonzalez-Lira G, Madrigal-de la Campa A. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 2001;93:1325-30.
11. Hecht JL, Kadish AS, Jiang G, Burk R. Genetic characterization of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential. Int J Cancer 1995;60:369-76.
12. Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrera R, Rodriguez A, Bratti MC, Sherman ME, Scarpidis U, Lin QQ, Terai M, Bromley RL, et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001;93:315-18.
13. Xi LF, Carter JJ, Galloway DA, Kuypers J, Hughes JP, Lee SK, Adam DE, Kiviat NB, Koutsky LA. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 2002;11:343-51.
14. Burk RD, Terai M, Gravitt PE, Brinton LA, Kurman RJ, Barnes WA, Greenberg MD, Hadjimichael OC, Fu L, McGowan L, Mortel R, Schwartz PE, et al. Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res 2003;63:7215-20.
15. Lizano M, Berumen J, Guido MC, Casas L, Garcia-Carranca A. Association between human papillomavirus type 18 variants and histopathology of cervical cancer. J Natl Cancer Inst 1997;89:1227-31.
16. Zehbe I, Voglino G, Delius H, Wilander E, Tommasino M. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 1998;352:1441-2.
17. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69:364-8.
18. Bontkes HJ, van Duin M, de Gruijl TD, Duggan-Keen MF, Walboomers JM, Stukart MJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ, Stevens FR, Dyer FR, et al. HPV-16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV-16 E6 sequence variants. Int J Cancer 1998;78:166-71.
19. Brady CS, Duggan-Keen MF, Davidson JA, Varley JM, Stern PL. Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters. J Gen Virol 1999;80:3233-40.
20. Nindl I, Rindfleisch K, Lotz B, Schneider A, Dütrst M. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer 1999;82:203-7.
21. Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G, Ludwig-McGill Study Group. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papilloma-virus infection and cervical neoplasia in Brazil. Rev Panam Salud Publica 1999;6:223-33.
22. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polimerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989;7:209-14.
23. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
24. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487-91.
25. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
26. Wheeler CM, Yamada T, Hildesheim A, Jenison SA. Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. J Clin Microbiol 1997;35:11-19.
27. Picconi MA, Alonio LV, Sichero L, Mbayed V, Villa LL, Gronda J, Campos R, Teyssie A. Human papillomavirus type-16 variants in Quechua aboriginals from Argentina. J Med Virol 2003;69:546-52.
28. Schlecht NF, Burk RD, Palefsky JM, Minkoff H, Xue X, Massad LS, Bacon M, Levine AM, Anastos K, Gange SJ, Watts DH, Da Costa MM, et al. Variants of human papillomavirus 16 and 18 and their natural history in human immunodeficiency virus-positive women. J Gen Virol 2005;86:2709-20.
29. Mayrand MH, Coutlee F, Hankins A, Lapointe N, Forest P, de Ladurantaye M, Roger M. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J Clin Microbiol 2000;38:3388-93.
30. Aho J, Hankins C, Tremblay C, Forest P, Pourreaux K, Rouah F, Coutlee F, Canadian Women's HIV Study Group. Genomic polymorphism of human papillomavirus type 52 predisposes toward persistent infection in sexually active women. J Infect Dis 2004;190:46-52.
31. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, Cheung JL, Cheng AF. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 2002;94:1249-53.
32. Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, Koutsky LA. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst 2006;98:1045-1052.
33. Terry G, Ho L, Cuzick J. Analysis of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type. Int J Cancer 1998;73:651-5.
34. Zehbe I, Mytilineos J, Wikstrom I, Henriksen R, Edler L, Tommasino M. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol 2003;64:538-42.
35. van Belkum A, Juffermans L, Schrauwen L, van Doornum G, Burger M, Quint W. Genotyping human papillomavirus type 16 isolates from persistently infected promiscuous individuals and cervical neoplasia patients. J Clin Microbiol 1995;33:2957-62.
36. Kämmer C, Warthorst U, Torrez-Martinez N, Wheeler CM, Pfister H. Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for P97 promoter activity. J Gen Virol 2000;81:1975-81.
37. Sichero L, Franco EL, Villa LL. Different P105 promoter activity among natural variants of human papillomavirus type 18. J Infect Dis 2005;191:739-42.
38. Veress G, Szarka K, Dong XP, Gergely L, Pfister P. Functional significance of sequence variation in the E2 gene and the long control region of human papillomavirus type 16. J Gen Virol 1999;80:1035-43.
39. Choo KB, Wang TS, Huang CJ. Analysis of relative binding affinity of E7-pRB of human papillomavirus 16 clinical variants using the yeast two-hybrid system. J Med Virol 2000;61:298-302.
40. Hsieh CH, Tsao YP, Wang CH, Han CP, Chang JL, Lee JY, Chen SL. Sequence variants and functional analysis of human papillomavirus type 16 E5 gene in clinical specimens. Arch Virol 2000;145:2273-84.
41. Villa LL, Schlegel R. Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virology 1991;181:374-7.
42. Stöppler MC, Ching K, Stöppler H, Clancy K, Schlegel R, Icenogle J. Natural variants of human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 1996;70:6987-93.
43. Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, Krishna S. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol 2004;78:5934-45.
44. Ordoñez RM, Espinosa AM, Sanchez-Gonzalez DJ, Armendariz-Borunda J, Berumen J. Enhanced oncogenicity of Asian-American human papillomavirus 16 is associated with impaired E2 repression of E6/E7 oncogene transcription. J Gen Virol 2004;85:1433-44.
45. Casas L, Galvan SC, Ordoñez RM, Lopez N, Guido M, Berumen J. Asian-American variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas. Int J Cancer 1999;83:449-55.
46. Hubert WG. Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the viral life cycle. J Virol 2005;79:5914-22.
47. Kirnbauer R, Taub J, Greenstone H, Roden R, Dürst M, Gismann L, Lowy DR, Schiller JT. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993;67:6929-36.
48. Touze A, El Mehdaoui S, Sizaret PY, Mougin C, Muñoz N, Courssaget P. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol 1998;36:2046-51.
49. Cheng G, Icenogle JP, Kirnbauer R, Hubert NL, StLouis ME, Han C, Svare EI, Kjaer SK, Lowy DR, Schiller JT. Divergent human papillomavirus type 16 are serologically cross-reactive. J Infect Dis 1995;172:1584-7.
50. Nindl I, Zumbach K, Pawlita M, Teller K, Schneider A, Dürst M. Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations. J Infect Dis 2000;181:1764-67.
51. Pastrana DV, Vass WC, Lowy DR, Schiller JT. HPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 2001;279:361-9.